Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Fate Therapeutics news
05.05.2022
Fate Therapeutics reported a GAAP loss of $65.69 million for the first 3 months of 2022, up 45.7% from $45.089 million in the prior year. Revenue increased 65.3% to $18.414 million from $11.142 million a year earlier.
Source: 
ir.fatetherapeutics.com
ir.fatetherapeutics.com
01.03.2022
Fate Therapeutics' GAAP loss for 2021 was $212.151 million, up 22.4% from $173.387 million in the previous year. Revenue increased 77.7% to $55.846 million from $31.434 million a year earlier.
Source: ir.fatetherapeutics.com
ir.fatetherapeutics.com
05.11.2021
Fate Therapeutics reported a GAAP loss of $143.53 million for 9M 2021, up 19.3% from $120.276 million in the previous year. Revenue increased 2.5 times to $38.777 million from $15.538 million a year earlier.
Source: ir.fatetherapeutics.com
ir.fatetherapeutics.com
04.08.2021
Fate Therapeutics' GAAP loss for the six months of 2021 was $100.222 million, up 62.7% from $61.592 million in the prior year. Revenue increased 3.1 times to $24.552 million from $7.98 million a year earlier.
Source: ir.fatetherapeutics.com
ir.fatetherapeutics.com
General information
| Company name | Fate Therapeutics |
|---|---|
| Tags | #katie wood's choice, #biotechnology |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121 858.875.1803 |
| Mailing address | 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121 |
| Website | www.fatetherapeutics.com |
| Information disclosure | www.sec.gov |
English (US) 